Alx oncology receives u.s. fda orphan drug designation for evorpacept for the treatment of patients with acute myeloid leukemia

South san francisco, calif., june 29, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that the u.s. food and drug administration (“fda”) granted orphan drug designation (“odd”) to evorpacept, a next-generation cd47 blocker, for the treatment of patients with acute myeloid leukemia (“aml”).
ALXO Ratings Summary
ALXO Quant Ranking